INTRODUCTION
============

Increased urinary protein excretion is a risk factor for progression of chronic kidney disease (CKD) and is strongly associated with adverse cardiovascular outcomes.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4]^ The presence of proteinuria markedly increases cardiovascular and renal risk at any level of estimated glomerular filtration rate (eGFR) and identifies additional people who are at high risk despite normal or nearly normal eGFR.^[@bib5]^ Proteinuria measurements have thus been used to identify patients who are most likely to benefit from treatment using current renoprotective strategies.^[@bib1],\ [@bib6],\ [@bib7]^ These data highlight the importance of proteinuria as a prognostic marker in patients with CKD and also as a potential tool for guiding treatment.

Studies in patients with chronic diseases (including CKD) have suggested that remote-dwelling patients are at particularly high risk for suboptimal care and adverse outcomes---due in part to documented gaps between recommended practice and real-world clinical performance.^[@bib7],\ [@bib8],\ [@bib9]^ This issue is especially germane for large countries such as Canada, where rural/remote residence is common and nephrologists often practice only in larger centers.

We sought to determine the prevalence of heavy proteinuria among remote dwellers in Alberta, investigate the association between remoteness and markers of good-quality care, and assess the association between such markers and clinical outcomes.

RESULTS
=======

Of 3,897,684 eligible patients, 2,441,306 were excluded due to the absence of a measure of proteinuria (*n*=1,885,976) or eGFR (*n*=480,671), being underaged (*n*=69,102), and death out of province or having stage 5 CKD prior to the study start date (*n*=5557). The baseline demographic and clinical characteristics of the study population are shown in [Table 1](#tbl1){ref-type="table"}. Across distance categories, one-fifth of the population resided in remote areas \>50 km from the closest nephrologist ([Table 1](#tbl1){ref-type="table"}). Remote dwellers were slightly older, were more likely to be Aboriginal, and were more likely to have hypertension, diabetes, and more advanced CKD compared to urban dwellers.

Prevalence of heavy proteinuria
-------------------------------

The overall prevalence of heavy proteinuria was 2.3%, 2.9%, and 2.5% in those who live \>200, 100.1--200, and 50.1--100 km, respectively (*P*\<0.001), as compared to 1.5% in those who live within 50 km of the closest nephrologist ([Figure 1](#fig1){ref-type="fig"}). The prevalence was 1.6% and 2.4% among urban and rural dwellers, respectively (*P*\<0.001). The prevalence of proteinuria (using several definitions) was higher across all stages of CKD in the remote dwellers compared to the urban dwellers ([Table 2](#tbl2){ref-type="table"}).

Guideline-recommended care in patients with heavy proteinuria
-------------------------------------------------------------

There was no significant negative association between the presence of heavy proteinuria and markers of quality care and remoteness or rural residence ([Table 3](#tbl3){ref-type="table"}).

Clinical outcomes among those with heavy proteinuria
----------------------------------------------------

The clinical outcomes of all-cause mortality, myocardial infarction, stroke, heart failure, doubling of serum creatinine (Scr), and end-stage renal disease (ESRD) occurred overall in 4307 (19.1), 675 (3.0), 600 (2.7), 1120 (5.0), 1350 (6.0), and 1927 (8.5) patients, respectively. There were no significant differences in the likelihood of all-cause mortality, myocardial infarction, heart failure, doubling of Scr, and development of ESRD across the travel distance categories ([Table 3](#tbl3){ref-type="table"}); however, there was a higher incidence of stroke in those travelling a greater distance to the nephrologist (hazards ratio (HR): 1.37 (95% confidence interval 1.03--1.83)) in the 100.1--200 km distance category; and HR: 1.35 (1.03--1.78) in the \>200 km distance category; *P* for trend 0.02. The all-cause hospitalization rate was significantly greater in remote dwellers as compared with urban dwellers (relative rate: 1.33 (1.29--1.38); *P*\<0.001).

Sensitivity analysis
--------------------

Sensitivity analyses on the subgroup of subjects with diabetes and heavy proteinuria showed similar results (data not shown).

DISCUSSION
==========

This study examined the burden of heavy proteinuria---focusing on the link between quality of care and clinical outcomes in people with this condition who live in remote Alberta communities. We aimed to identify opportunities to improve clinical outcomes in remote dwellers with heavy proteinuria. In this study of over 1.3 million people, we found that the prevalence of heavy proteinuria is especially common in people living in rural and remote areas of Alberta. Although markers of high-quality care (i.e. use of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs) and statins) were equally common in remote dwellers and urban dwellers, we noted an increased risk of stroke and all-cause hospitalizations in remote dwellers.

In previous studies, we have demonstrated that markers of good-quality care are less prevalent among rural and remote dwellers with non-dialysis-dependent CKD, and among remote dwellers with ESRD,^[@bib9],\ [@bib10]^ and that remote dwellers also have worse outcomes as compared to otherwise similar clinical outcomes. What this study adds to the existing literature is the finding that heavy proteinuria is common in the community and even more common in remote dwellers. However, unlike the general CKD population, gaps in care are equally pronounced in both remote and urban dwellers. This information has significant implications for policy-makers in planning clinical care for patients with proteinuria and CKD living in remote locations of Alberta and elsewhere. Specifically, since remote dwellers have a higher burden of heavy proteinuria, strategies aimed at improving care in this population will have to take into account the additional barriers to care faced by rural dwellers.^[@bib8]^ The large numbers of affected people suggest that nephrologists will be unable to address the problem alone. For example, decision makers might consider co-management of patients by community practitioners (including primary-care physicians, community health workers, nurse practitioners) using pre-specified management guidelines and/or protocols.

Why did remote dwellers have a higher frequency of proteinuria? The major established risk factors for proteinuria include diabetes, hypertension, obesity, cardiovascular disease, smoking, age, and race. In our study, the remote dwellers were indeed older and more likely to have diabetes, hypertension, and to be Aboriginal than the urban dwellers. Of note, our sensitivity analyses stratified based on presence/absence of diabetes did not show any significant differences on quality-of-care delivery and clinical outcomes in the study population.

Our study has several potential strengths. First, it was a population-based study of a single Canadian province, involving a relatively homogenous population. Second, it included more than 1.3 million subjects from which individuals with heavy proteinuria were identified. However, our study also has some limitations, including the known inaccuracies of urine dipstick analysis, and the fact that most subjects in the study had only a single measurement of proteinuria and eGFR. However, results were similar in the subset of participants with multiple measures and/or persistent proteinuria.

In conclusion, heavy proteinuria is common in Alberta residents, especially in remote dwellers. Given the higher risk of adverse outcomes in those with proteinuria, strategies aimed at improving care in this high-risk population will have to take into account the additional barriers to care faced by the remote dwellers. Care and outcomes seems similar across categories of travel distance, but with higher risk of hospitalizations and stroke among remote dwellers. This has policy and practice implications for CKD care in remote communities, and further work is needed to understand the basis of increased risk of hospitalizations and stroke, which may be partly related to a higher burden of proteinuria and comorbidities among the remote dwellers.

METHODS
=======

Population and data sources
---------------------------

We studied all adults, 18 years and older, residing in Alberta with at least one measure of urine protein (albumin:creatinine ratio (ACR), protein:creatinine ratio (PCR), or protein dipstick urinalysis) and a measure of Scr concentration between May 2002 and March 2009. Participants with ESRD (eGFR\<15 ml/min per 1.73 m^2^; chronic dialysis; prior kidney transplant) at baseline were excluded. Data were drawn from Alberta Health and Wellness, Alberta Blue Cross, the Northern and Southern Alberta Renal Programs (NARP and SARP), and the provincial laboratories of Alberta.^[@bib12]^

Definitions and classifications
-------------------------------

Heavy proteinuria was defined by the presence of ACR ⩾60 mg/mmol, PCR ⩾100 mg/mmol,^[@bib13]^ or protein ⩾2+ on dipstick urinalysis. Estimated GFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and categorized as ⩾60, 45--59.9, 30--44.9, and 15--29.9 ml/min per 1.73 m^2^. In a sensitivity analysis, we evaluated persistent proteinuria, defined as two or more measurements demonstrating proteinuria within 6 months of the index date, and high-grade proteinuria, defined as the presence of ACR ⩾180 mg/mmol, PCR ⩾300 mg/mmol, or protein ⩾3+ on dipstick urinalysis.

Demographic variables included age (categorized as 18--49.9, 50--69.9, and ⩾70), gender, Aboriginal (registered First Nations or recognized Inuit), and social assistance. We used validated algorithms to define the Charlson comorbidities and hypertension^[@bib14]^ using the AHW physician claims and hospitalization databases. The Charlson score was based on the Deyo classification^[@bib15]^ of the following comorbidities: cerebrovascular disease, peripheral vascular disease, congestive heart failure, cancer, COPD, dementia, diabetes with and without complications, AIDS/HIV, metastatic solid tumor, myocardial infarction, mild liver disease, moderate/severe liver disease, paralysis, peptic ulcer disease, and rheumatic disease.

Evaluation of residence location
--------------------------------

We calculated the geographic coordinates for each patient\'s residence using the Canadian Postal Code conversion file (PCCF),^[@bib16]^ and determined the practice location of the closest nephrologist and closest internal medicine specialist. The geographic coordinates for each 6-digit postal code were determined using the Statistics Canada PCCF ([www.statcan.ca](http://www.statcan.ca)). These coordinates were entered into ESRI ArcInfo 9.3 software ([www.esri.com](http://www.esri.com)) to determine the shortest distance by road (in km) between the residence of each patient and the practice location of the closest specialist. As in our previous work, we categorized driving distance to the closest specialist into the following *a priori* categories: 0--50, 50.1--100, 100.1--200, and \>200 km.^[@bib10]^ Rural or urban residence was defined at the postal code level using the Statistics Canada definition as recorded in the PCCF.

Markers of good quality of care (process-based outcomes) among patients with proteinuric CKD
--------------------------------------------------------------------------------------------

Markers of good quality of care were: referral to any nephrologist within 18 months of the index date, ACEi or ARB, and statin usage. Prescription use was evaluated in the subset of participants aged 65 years and above, all of whom had government-sponsored drug insurance. Medication usage was defined as at least one prescription within 6 months of the index date.

Clinical outcomes
-----------------

Clinical outcomes included all-cause mortality; number of hospitalizations; cardiovascular events including heart failure, myocardial infarction, and stroke; ESRD; and sustained doubling of Scr concentration (a surrogate measure for progressive kidney disease) as previously defined.^[@bib5]^

Statistical analyses
--------------------

The analyses were done with Stata/MP 11.1 ([www.stata.com](http://www.stata.com)). Baseline descriptive statistics were reported as counts and percentages, or medians and interquartile ranges, as appropriate. Prevalence of heavy proteinuria was calculated overall and for CKD-EPI eGFR subgroups, by distance to the closest nephrologist, and rural or urban residence. In sensitivity analyses, heavy proteinuria was defined by ACR or PCR measurements alone.

The associations between distance and quality-of-care outcomes were estimated using logistic, Cox, and Poisson regression models as appropriate. Follow-up was censored when a participant died, moved out of province, or was at the end of study (March 2009). Models were adjusted for all variables presented in [Table 1](#tbl1){ref-type="table"}. The threshold *P* for statistical significance was set at 0.05. We did sensitivity analyses on the subgroup of subjects with diabetes and proteinuria.
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![**Prevalence of heavy proteinuria by distance to the closest nephrologist.** The x-axis represents the travel distance categories (km) with the width of each bar representing the proportion of participants (%) in each distance category. The y-axis represents the distribution of the various categories of proteinuria (%) (none, heavy, high grade). The height of each colored segment within a bar represents the proportion of participants in that category of proteinuria. None=no proteinuria; heavy=heavy proteinuria (ACR⩾60 mg/mmol, PCR⩾100 mg/mmol, or protein ⩾2+ on dipstick urinalysis); high grade=high-grade proteinuria (ACR⩾180 mg/mmol, PCR⩾300 mg/mmol, or protein ⩾3+ dipstick on urinalysis). The left panel shows all participants (*N*=1,359,330). The right panel shows participants at high risk for proteinuric CKD (*N*=394,354).](kisup201326f1){#fig1}

###### Demographic and clinical characteristics of participants by distance to closest nephrologist

                                                   **Urban**           **Rural**      ***P***      **0--50 km**     **50.1--100 km**    **100.1--200 km**     **\>200 km**     ***P* for trend**
  -------------------------------------------- ------------------ ------------------- --------- ------------------ ------------------- ------------------- ------------------- -------------------
  *N*[a](#t1-fn2){ref-type="fn"}                1,205,760 (88.8)    151,689 (11.2)    ---        1,097,121 (80.7)     106,326 (7.8)       61,068 (4.5)        94,815 (7.0)     ---
                                                                                                                                                                                
  *eGFR, ml/min per 1.73 m*^*2*^                                                                                                                                               
   ⩾60                                          1,115,496 (92.5)    138,365 (91.2)    \<0.001    1,018,217 (92.8)      94,658 (89)        54,604 (89.4)       88,135 (93.0)    \<0.001
   45--59.9                                       61,208 (5.1)        9054 (6.0)      \<0.001      54,142 (4.9)        7701 (7.2)          4153 (6.8)          4348 (4.6)      0.56
   30--44.9                                       22,182 (1.8)        3238 (2.1)      \<0.001      19,047 (1.7)        2977 (2.8)          1724 (2.8)          1706 (1.8)      \<0.001
   15--29.9                                        6874 (0.6)         1032 (0.7)      \<0.001       5715 (0.5)          990 (0.9)           587 (1.0)           626 (0.7)      \<0.001
                                                                                                                                                                                
  Age, years                                    47.7 (36, 59.8)    51.4 (40.4, 62.8)  \<0.001    47.6 (36, 59.5)    53.0 (41.4, 65.4)    52.2 (39.9, 65)    47.0 (34.9, 58.2)  \<0.001
  Male                                           560,004 (46.4)      72,118 (47.5)    \<0.001     510,735 (46.6)      49,317 (46.4)       28,408 (46.5)        44,527 (47)     0.02
  Aboriginal                                      16,296 (1.4)       10,401 (6.9)     \<0.001      13,434 (1.2)        5707 (5.4)          2070 (3.4)          5570 (5.9)      \<0.001
  Social assistance                                36,619 (3)         3669 (2.4)      \<0.001      32,882 (3.0)        3198 (3.0)          1922 (3.1)          2325 (2.5)      \<0.001
                                                                                                                                                                                
  *Comorbidities*                                                                                                                                                              
   Charlson score[b](#t1-fn3){ref-type="fn"}        0 (0, 1)           0 (0, 1)       \<0.001        0 (0, 1)           0 (0, 1)            0 (0, 1)            0 (0, 1)       \<0.001
   Diabetes                                       94,734 (7.9)       15,650 (10.3)    \<0.001      82,451 (7.5)       12,089 (11.4)        7087 (11.6)         8928 (9.4)      \<0.001
   Hypertension                                  292,255 (24.2)      44,683 (29.5)    \<0.001     258,990 (23.6)      34,818 (32.7)       19,857 (32.5)       23,736 (25.0)    \<0.001

Abbreviations: AIDS, acquired immune deficiency syndrome; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration formula; HIV, human immunodeficiency virus; PVD, peripheral vascular disease.

1925 participants could not be classified according to urban or rural status.

Charlson score includes AIDS/HIV, metastatic cancers, non-metastatic cancers, cerebral vascular disease, chronic obstructive pulmonary disease, dementia, diabetes, heart failure, mild liver disease, moderate/severe liver disease, myocardial infarction, paraplegia, peptic ulcer, peripheral vascular disease, and rheumatological disease. *N* (%) or the median and inter-quartile range are presented.

###### Prevalence of clinically relevant proteinuria by distance to the closest nephrologist

  **Events (%)**                                                  **Urban**      **Rural**    ***P***   **0--50 km**   **50.1--100 km**   **100.1--200 km**   **\>200 km**   ***P* for trend**
  --------------------------------------------------------------- -------------- ------------ --------- -------------- ------------------ ------------------- -------------- -------------------
  Heavy proteinuria                                               19,399 (1.6)   3673 (2.4)   \<0.001   16,278 (1.5)   2755 (2.5)         1829 (2.9)          2244 (2.3)     \<0.001
                                                                                                                                                                              
  *Proteinuria by eGFR*                                                                                                                                                      
   ⩾60                                                            13,331 (1.2)   2522 (1.8)   \<0.001   11,175 (1.1)   1839 (1.9)         1241 (2.2)          1618 (1.8)     \<0.001
   45--59.9                                                       2560 (4.1)     521 (5.6)    \<0.001   2132 (3.8)     402 (5.1)          276 (6.4)           278 (6.2)      \<0.001
   30--44.9                                                       2024 (8.8)     363 (10.8)   \<0.001   1731 (8.8)     271 (8.9)          189 (10.6)          200 (11.1)     \<0.001
   15--29.9                                                       1484 (20.9)    267 (24.7)   0.004     1240 (21)      243 (23.5)         123 (20.1)          148 (22.9)     0.28
                                                                                                                                                                              
  Persistent proteinuria                                          9077 (0.7)     1646 (1.1)   \<0.001   7713 (.7)      1341 (1.2)         786 (1.3)           901 (0.9)      \<0.001
  Proteinuria as defined by ACR or PCR only                       4088 (0.3)     773 (0.5)    \<0.001   3534 (0.3)     717 (0.7)          326 (0.5)           291 (0.3)      0.13
  High-grade proteinuria                                          5624 (0.5)     1087 (0.7)   \<0.001   4672 (0.4)     754 (0.7)          510 (0.8)           789 (0.8)      \<0.001
  Proteinuria in high-risk[a](#t2-fn2){ref-type="fn"} groups      11,045 (3.2)   2183 (4.1)   \<0.001   9233 (3)       1698 (4.1)         1109 (4.7)          1208 (4.1)     \<0.001
  Proteinuria as defined by ACR or PCR only in high-risk groups   3621 (1)       711 (1.3)    \<0.001   3127 (1)       658 (1.6)          296 (1.2)           257 (0.9)      0.42
  Incident proteinuria in high-risk groups                        8371 (2.4)     1708 (3.2)   \<0.001   6866 (2.2)     1384 (3.3)         956 (4)             891 (3.1)      \<0.001

Abbreviations: ACR, albumin:creatinine ratio; eGFR, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration formula; PCR, protein:creatinine ratio.

Those with diabetes, hypertension, coronary disease, peripheral vascular disease, and/or eGFR\<60 ml/min per 1.73 m^2^.

Heavy proteinuria=presence of ACR ⩾60 mg/mmol, PCR ⩾100 mg/mmol or protein ⩾2+ on dipstick urinalysis.

High-grade proteinuria=presence of ACR ⩾180 mg/mmol, PCR ⩾300 mg/mmol or protein ⩾3+ dipstick on urinalysis.

Persistent proteinuria defined as two or more measurements demonstrating proteinuria within 6 months of the index date.

###### Care and clinical outcomes by distance to the closest nephrologist in subjects with heavy proteinuria

                                      **Events/*N***  **Rural**           **0-50 km**   **50.1--100 km**    **100.1--200 km**   **\>200 km**        ***P* for trend**
  ---------------------------------- ---------------- ------------------- ------------- ------------------- ------------------- ------------------- -------------------
  ACEi/ARB use in ⩾65 years             4128/7760     0.85 (0.74, 0.96)   1.0           0.88 (0.76, 1.01)   0.84 (0.71, 0.99)   1.04 (0.87, 1.24)   0.97
  Statin use in ⩾65 years               2468/7760     0.99 (0.87, 1.14)   1.0           1.00 (0.86, 1.16)   0.98 (0.83, 1.17)   1.00 (0.83, 1.20)   0.98
  Timely referral                      4602/22,599    0.72 (0.63, 0.83)   1.0           0.82 (0.71, 0.94)   0.52 (0.43, 0.63)   0.46 (0.38, 0.56)   \<0.001
                                                                                                                                                     
  *HR (95% CI)*                                                                                                                                     
   All-cause mortality                 4307/22,599    0.99 (0.91, 1.08)   1.0           1.15 (1.05, 1.27)   1.10 (0.98, 1.23)   1.04 (0.93, 1.17)   0.32
   Myocardial infarction                675/22,599    0.78 (0.62, 0.99)   1.0           1.00 (0.78, 1.27)   0.62 (0.42, 0.90)   1.12 (0.86, 1.46)   0.68
   Stroke                               600/22,599    1.13 (0.90, 1.41)   1.0           1.19 (0.93, 1.53)   1.37 (1.03, 1.83)   1.35 (1.03, 1.78)   0.02
   Heart failure                       1120/22,599    1.07 (0.91, 1.26)   1.0           1.23 (1.03, 1.47)   0.95 (0.75, 1.20)   0.89 (0.70, 1.12)   0.31
   Doubling of SCr                     1350/22,599    1.00 (0.85, 1.16)   1.0           1.17 (0.98, 1.38)   1.11 (0.89, 1.39)   1.06 (0.88, 1.29)   0.47
   ESRD[a](#t3-fn2){ref-type="fn"}     1927/22,599    0.91 (0.79, 1.03)   1.0           1.13 (0.98, 1.30)   0.83 (0.68, 1.02)   1.03 (0.87, 1.21)   0.93
                                                                                                                                                     
  *Relative rate (95% CI)*                                                                                                                          
   Hospitalizations                   34,481/22,599   1.33 (1.29, 1.38)   1.0           1.54 (1.49, 1.59)   1.58 (1.52, 1.65)   1.57 (1.51, 1.64)   \<0.001

Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin:creatinine ratio; ARB, angiotensin receptor blocker; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration formula; ESRD, end-stage renal disease; HR, hazard ratio; OR, odds ratio; PCR, protein:creatinine ratio; SCr, serum creatinine ratio.

Includes eGFR \<15 ml/min per 1.73 m^2^.

Values are shown as OR (95% CI) unless otherwise indicated.

Results were adjusted for eGFR (⩾60, 45--59.9,30--44.9,15--29.9), age (18--49.9, 50--69.9, ⩾70), gender, aboriginal, social assistance, and comorbidities (Charlson score, hypertension).
